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The recent determination of X-ray structures of pharmacologically relevant GPCRs has made these
targets accessible to structure-based ligand discovery. Here we explore whether novel chemotypes may
be discovered for the A2A adenosine receptor, based on complementarity to its recently determined
structure. The A2A adenosine receptor signals in the periphery and the CNS, with agonists explored as
anti-inflammatory drugs and antagonists explored for neurodegenerative diseases. We used molecular
docking to screen a 1.4 million compound database against the X-ray structure computationally and
tested 20 high-ranking, previously unknown molecules experimentally. Of these 35% showed sub-
stantial activity with affinities between 200 nM and 9 μM. For the most potent of these new inhibitors,
over 50-fold specificity was observed for the A2A versus the related A1 and A3 subtypes. These high hit
rates and affinities at least partly reflect the bias of commercial libraries towardGPCR-like chemotypes,
an issue that we attempt to investigate quantitatively. Despite this bias, many of the most potent new
ligands were novel, dissimilar from known ligands, providing new lead structures for modulation of this
medically important target.
Introduction
G-protein-coupled receptors (GPCRsa) are a large family
of transmembrane proteins that signal intracellularly after
bindinganextracellular ligand.These receptors share a similar
topology, with seven transmembrane helices, but recognize a
wide range of different signalingmolecules.GPCRs have been
intensely studied as pharmaceutical targets, and over 40% of
marketed drugs act through them.1 Until recently, a missing
link to deeper understanding of GPCRs has been a lack of
atomic resolution structural information. With the recent
advent of several X-ray crystal structures of pharmacologi-
cally relevant GPCRs2-5 it has for the first time become
possible to leverage high-resolution structures for ligand
discovery against these targets.6
Among the new GPCR structures is that of the A2A adeno-
sine receptor (AR).5 There are four subtypes of the AR (A1,
A2A, A2B, and A3), and they are activated by extracellular
adenosine in response to organ stress or tissue damage. The
A2A AR signals in both the periphery and the CNS, with
agonists explored as anti-inflammatory drugs and antagonists
explored for neurodegenerative diseases, e.g., Parkinson’s
disease.7-11 Although access to high resolution structural data
is a crucial step toward atomic-level understanding ofGPCRs,
the lack of structures has certainly not been an obstacle for
successful ligand discovery. For several decades, classical
ligand-based medicinal chemistry approaches have been used
to identify thousands of AR ligands. Almost all known AR
agonists are derivatives of the cognate ligand (1-3, Chart 1),
whereas antagonists aremore diverse. Two large classes ofAR
antagonists are xanthines, with members such as caffeine (4)
and theophylline (5), and adenine derivates such as 6
(ZM24138512), which is bound to the A2A AR binding site
in the crystallographic structure (Chart 1, Figure 1A).
Despite considerable medicinal chemistry efforts and the
wide range of possible therapeutic applications for AR
ligands, there are only a few approved drugs targeting this
receptor.8,11 Consequently, there remains an ongoing need
for new subtype selective agonists and antagonists of this
target.
Here, we wished to investigate whether we could find new
A2A AR ligand chemotypes by using structure-based mole-
cular docking to screen a large and putatively unbiased library
of small molecules, looking for those that complement the
receptor structure. Docking evaluates the complementarity
of small molecules to a receptor binding site of known
structure13-18 and can in principle discover new chemotypes,
dissimilar to previous ligands, that nevertheless fit the binding
site well. Such chemotypes might provide new routes for
modulation of this key target. Methodologically, we wanted
to explore what the hit rate of a structure-based (docking)
screen against the A2A AR might be. In docking screens
against the β2 adrenergic GPCR, a hit rate of 24% had been
observed.19-23 A docking “hit” is a molecule that binds to the
target at a relevant concentration, and a docking “hit rate” is
the number of compounds that bind divided by the number of
compounds experimentally tested. For the β2 adrenergic
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receptor, where the affinity of the best docking hit was 9 nM,
both were unusually high. We wished to understand whether
this would be true for this second GPCR and why this might
be so. To investigate this, we docked a library of 1.4 million
small molecules to the crystal structure of the A2A AR. From
the top-scoring molecules, 20 were selected on the basis of
their fit to the binding site and chemical diversity. Here, we
present the experimental evaluation of these molecules and
assess why GPCRs appear to be particularly suitable targets
for structure-based ligand discovery.
Methods
Preparation of the Molecular Docking Screen. All dock-
ing calculations were carried out with the program DOCK
3.5.5416,17,24 using a 2.6 A˚ crystallographic structure of the
A2A adenosine receptor in complex with an antagonist (6)
12
(PDB accession code 3EML5). The receptor structure was
prepared by removing all non-protein atoms and the intracellu-
lar T4-lysozyme insertion. The protonation states of ionizable
residueswere set to themostprobable in aqueous solution at pH7.
The flexible-ligand sampling algorithm in DOCK3.5.54
superimposes atoms of the docked molecule onto binding site
matching spheres, which indicate putative ligand atom posi-
tions.16,17 In the case of the A2A AR, 45 matching spheres were
used, and these were either based on the atoms of the crystallo-
graphic ligand or positioned manually. The spheres were also
labeled for chemical matching based on the local receptor
environment.25 The degree of ligand sampling is determined
by the bin size, bin size overlap, and distance tolerance. These
three parameters were set to 0.4, 0.3, and 1.5 A˚, respectively, for
both the binding site matching spheres and the docked mole-
cules. For ligand conformations passing an initial steric filter, a
physics-based scoring function is used to evaluate the fit to the
receptor binding site. For the best scoring conformation of each
docked molecule, 100 steps of rigid-body minimization are
carried out. The score for each conformation is calculated as
the sum of the receptor-ligand electrostatic and van der Waals
interaction energy, corrected for ligand desolvation. These three
terms are evaluated from precalculated grids. The three-dimen-
sional map of the electrostatic potential in the binding site was
prepared using the programDelphi.26 In this calculation, partial
charges from the united atom AMBER force field27 were used
Chart 1. Structures of Known Agonists (1-3) and Antagonists (4-6) of the A2A Adenosine Receptor
Figure 1. Bindingmode of the cocrystallized ligand 6 (A) and the predicted bindingmodes of the seven ligands discovered in the docking screen
(B-H). TheA2AARbinding site is shown inwhite ribbonswith the side chains ofGlu169 andAsn253 in sticks. In (A) the cocrystallized ligand 6
is shown using orange carbon atoms. In (B-H), the crystallographic ligand is shown using blue lines and the docking poses for the ligands are
depicted with orange carbon atoms. Black dotted lines indicate hydrogen bonds. The compounds are (B) 7, (C) 8, (D) 9, (E) 10, (F) 11, (G) 12,
and (H) 13.
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for all receptor atoms except the side chain amide of Asn253, for
which the dipole moment was increased to favor hydrogen
bonding to this residue (we have adopted this technique of
increasing local dipoles on a few polar residues in the active site
without changing their formal charges extensively in past
studies).28,29 The program CHEMGRID was used to generate
a van derWaals grid, which is based on a united atom version of
the AMBER force field.30 The desolvation penalty for a ligand
conformation is estimated from a precalculated transfer free
energy of the molecule between solvents of dielectrics 78 and 2.
The desolvation energy is obtained byweighting the transfer free
energy with a scaling factor that reflects the degree of burial of
the ligand in the receptor binding site.31,32
TheZINC leadlike set was prepared by filtering a large library
of commercially available compounds using the criteria logP<
3.5, molecular weight of <350, and number of rotatable bonds
of e7.33 Each molecule has been prepared for docking by
pregenerating up to 1000 conformations using the program
OMEGA.34 Partial atomic charges and transfer free energies
have been calculated using AMSOL,35,36 and van der Waals
parameters have been derived from an all-atom AMBER
potential.37
Similarity and Library Bias Calculations. Similarity calcula-
tions were carried out with the program Pipeline Pilot38 using
the Tanimoto coefficient and ECFP4 fingerprints. For each of
the docking-discovered ligands, the Tanimoto similarity to all
annotated A1, A2A, A2B, and A3 AR ligands withKie 10 μM in
the World of Molecular Bioactivity (WOMBAT 2006.2)39 and
ChEMBL (a StARlite 2009 prerelease version)40 databases was
calculated. The number of molecules in the ZINC leadlike
database that are similar to known ligands of the ARs, adre-
nergic receptors, adenylyl cyclases, and AmpC β-lactamase was
predicted with the similarity ensemble approach (SEA) using
ECFP4 fingerprints.41 Ligands (Kie 10 μM) that are annotated
to ARs, adrenergic receptors, and adenylyl cyclases were ex-
tracted from the WOMBAT database. Ligands for AmpC
β-lactamase were extracted from refs 28, 29, and 42. For each
ligand set, the number of leadlikemolecules in ZINC that have a
SEA P value better than 10-10 was calculated. The predicted
compounds were then postfiltered for molecules that match the
molecular weight and formal charge ranges of the known
ligands.
A2A AR Receptor Binding and Functional Assay. Binding
assays at three hAR subtypes were carried out using standard
radioligands43-45 and membrane preparations from Chinese
hamster ovary (CHO) cells (A1 and A3) or human embryonic
kidney (HEK293) cells (A2A) stably expressing a hAR sub-
type.46,47 A functional assay at the A2AAR consisted of stimula-
tion of cAMP production48,49 in A2AAR-expressing HEK293
cells. [3H]R-N6-(2-phenylisopropyl)adenosine ([3H]R-PIA, 42.6
Ci/mmol) was obtained from Moravek Biochemicals (Brea,
CA). [3H](2-[p-(2-Carboxyethyl)phenylethylamino]-50-N-ethyl-
carboxamidoadenosine) ([3H]CGS21680, 40.5 Ci/mmol) and
[125I]N6-(4-amino-3-iodobenzyl)adenosine-50-N-methylurona-
mide ([125I]I-AB-MECA, 2200 Ci/mmol) were purchased from
Perkin-Elmer Life and Analytical Science (Boston, MA). Test
compounds were prepared as 5 mM stock solutions in DMSO
and stored frozen at -20 C.
Cell Culture and Membrane Preparation. CHO cells stably
expressing the recombinant hA1 and hA3Rs, andHEK-293 cells
stably expressing the hA2AAR were cultured in Dulbecco’s
modified Eagle medium (DMEM) and F12 (1:1) supplemented
with 10% fetal bovine serum, 100 units/mL penicillin, 100 μg/
mL streptomycin, and 2 μmol/mL glutamine. In addition,
800 μg/mL Geneticin was added to the A2A media, while
500 μg/mL hygromycin was added to the A1 and A3 media.
After being harvested, cells were homogenized and suspended in
PBS. Cells were then centrifuged at 240g for 5min, and the pellet
was resuspended in 50 mMTris-HCl buffer (pH 7.5) containing
10 mMMgCl2. The suspension was homogenized and was then
ultracentrifuged at 14330g for 30 min at 4 C. The resultant
pellets were resuspended in Tris buffer and incubated with
adenosine deaminase (3 units/mL) for 30 min at 37 C. The
suspension was homogenized with an electric homogenizer for
10 s, pipetted into 1mL vials, and then stored at-80 Cuntil the
binding experiments were conducted. The protein concentration
was measured using the BCA protein assay kit from Thermo
Scientific Pierce Protein Research Products (Rockford, IL).50
Binding Assays. The tested compounds were purchased from
six different vendors (Enamine, ChemDiv, ChemBridge, Vitas-M,
Pharmeks, and Asinex). The vendors had verified that each
compound had g95% purity by liquid chromatography-mass
spectrometry (LC-MS) or nuclear magnetic resonance (NMR)
experiments. Into each tube in the binding assay was added 50 μL
of increasing concentrations of the test ligand in Tris-HCl buffer
(50 mM, pH 7.5) containing 10 mM MgCl2, 50 μL of the
appropriate agonist radioligand, and finally 100 μL of mem-
brane suspension. For the A1AR (22 μg of protein/tube)
the radioligand used was [3H]R-PIA (final concentration of
3.5 nM). For the A2AAR (20 μg/tube) the radioligand used
was [3H]CGS21680 (10 nM). For the A3AR (21 μg/tube) the
radioligand used was [125I]I-AB-MECA (0.34 nM). Nonspecific
binding was determined using a final concentration of 10 μM
unlabeled 50-N-ethylcarboxamidoadenosine (NECA, 2) diluted
with the buffer. Themixtures were incubated at 25 C for 60min
in a shaking water bath. Binding reactions were terminated by
filtration throughBrandelGF/B filters under a reduced pressure
using a M-24 cell harvester (Brandel, Gaithersburg, MD).
Filters were washed three times with 3 mL of 50 mM ice-cold
Tris-HCl buffer (pH 7.5). Filters for A1 and A2AAR binding
were placed in scintillation vials containing 5 mL of Hydrofluor
scintillation buffer and counted using a Perkin Elmer liquid
scintillation analyzer (Tri-Carb 2810TR). Filters for A3AR
binding were counted using a Packard Cobra II γ-counter.
The Ki values were determined using GraphPad Prism for all
assays.
Cyclic AMP Accumulation Assay. Intracellular cyclic AMP
(cAMP) levels were measured with a competitive protein bind-
ing method.48,49 CHO293 cells that expressed the recombinant
human A2AAR were harvested by trypsinization. After centri-
fugation and resuspension in medium, cells were planted in
24-well plates in 1.0 mL of medium. After 24 h, the medium was
removed and cells werewashed three times with 1mLofDMEM
containing 50 mMHEPES, pH 7.4. Cells were then treated with
the test compound in the presence of rolipram (10 μM) and
adenosine deaminase (3 units/mL), and incubation was contin-
ued for an additional 1 h. The reaction was terminated by
removing the supernatant, and cells were lysed upon the addi-
tion of 200 μL of 0.1 M ice-cold HCl. The cell lysate was
resuspended and stored at -20 C. For determination of cyclic
AMP production, protein kinase A (PKA) was incubated with
[3H]cyclic AMP (2 nM) in K2HPO4/EDTA buffer (K2HPO4,
150 mM; EDTA, 10 mM), 20 μL of the cell lysate, and 30 μL of
0.1MHCl or 50 μL of cyclic AMP solution (0-16 pmol/200 μL
for standard curve). Bound radioactivity was separated by rapid
filtration throughWhatmanGF/C filters and washed once with
cold buffer. Bound radioactivity was measured by liquid scin-
tillation spectrometry.
Counterscreen for Colloidal Inhibition. To control for artifac-
tual inhibition by colloidal aggregation, we looked for particle
formation by Dynamic Light Scattering (DLS) and by inhibi-
tion of two counterscreen enzymes, cruzain and AmpC
β-lactamase. Concentrated DMSO stocks of compounds were
diluted with filtered 50 mM KPi, pH 7.0. Measurements were
made using a DynaPro MS/X (Wyatt Technology) with a
55 mW laser at 826.6 nm. The laser power was 100%, and the
detector angle was 90. Cruzain assays were performed in
100 mM sodium acetate, pH 5.5, containing 5 mM DTT with
and without 0.1% Triton X-100. Compounds were incubated
with 0.8 nM cruzain for 5 min, and reactions were initiated by
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adding the fluorogenic substrate Z-Phe-Arg-aminomethylcou-
marin (Z-FR-AMC). The final reaction volumewas 200 μLwith
cruzain at 0.4 nM and ZF-R-AMC at 2.5 μM. Final DMSO
concentrations were 0.5%. To measure enzyme inhibition, the
increase in fluorescence (excitation wavelength of 355 nm,
emission wavelength of 460 nm) was recorded for 5 min in a
microtiter plate spectrofluorimeter (Molecular Devices, Flex-
Station). Assays were performed in duplicate in 96-well plates,
with controls measuring enzyme activity in the presence of
DMSO. Activity was measured for seven different concentra-
tions for each compound. Inhibition of AmpC β-lactamase was
measured for the two best compounds identified here, com-
pounds 9 and 11, to complement the cruzain assay results.
Assays were performed in 50 mM potassium phosphate, pH
7.0. Compounds were incubated with 1 nM β-lactamase for
5 min, and reactions were initiated by adding the substrate
CENTA to a final concentration 92 μM. The final reaction
volumewas 1mL. Tomeasure enzyme inhibition, the increase in
absorbance at 405 nm was recorded for 5 min in a UV-vis
spectrophotometer (Agilent). Assays were performed in dupli-
cate in 1 mL cuvettes, with controls measuring enzyme activity
in the presence of DMSO. Activity was measured at 10 μM,
0.1% DMSO.
Results and Discussion
Molecular Docking Screen and Compound Selection. The
program DOCK3.5.5416,17 was used to screen 1.4 million
commercially available “leadlike”molecules from the ZINC33
database against the orthosteric site of the A2A AR. On
average, each molecule was sampled in 5000 orientations
and, for each that fit, an average of 16 500 conformations;
the receptor was held rigid. Each molecule was scored for
electrostatic andvanderWaals complementarity corrected for
ligand desolvation. Molecules typically overlapped with the
geometry of the crystallized antagonist, making a mixture of
polar and hydrophobic interactions, packing deeply into the
site (Figure 1). The 500 top-ranking molecules (Table S1,
Supporting Information), 0.035% of the docking prioritized
library, were analyzed visually for features that are not taken
into account in the docking calculation. This is a standard
procedure for all our docking screens in which each of the
molecules is inspected for novelty, physical properties, and
binding energy contributions that are not included in the
docking scoring function. For example, compound 9 (Table 1)
was chosen both because it complemented the site well and
because there were several molecules with the same scaffold in
the top 500 list of compounds (e.g., the molecules ranked 7, 31,
59, 104, 115, 135, 137, 172, 184, 199, and 278 in Table S1,
Supporting Information). From this evaluation, 20 compounds
representingdiversemolecules (within the contextof the top500-
ranking molecules) were prioritized for experimental testing.
Radioligand Displacement Assays and Docking Hit Rate.
The 20 compounds selected from the docking screen were
tested for binding in a radioligand displacement assay. Seven
Table 1. Ligand Structures and Experimental Data for the Seven Hits from the Docking Screen against the A1, A2A, and A3 ARs
aRank in the docking screen. bMeasured in three independent experiments. cThe most similar compound annotated to ARs in WOMBAT39 and
ChEMBL.40 dTanimoto similarity coefficient to the closest annotated adenosine receptor ligand from ECFP4 fingerprints.
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of these molecules inhibited binding by g40% at 20 μM,
corresponding to a “hit rate” of 35%. Subsequent dose-
response curves were well-behaved, with Ki values varying
from 200 nM to 8.8 μM (Table 1 and Figure 2). Four of the
ligands, 9, 10, 11 and 13, were counterscreened for colloidal
aggregation, a common mechanism of artifactual inhibi-
tion.51 No colloidal particles were observed at 10 μM, by
dynamic light scattering, for 9 and 13, nor did they inhibit
cruzain at the same concentration. For compounds 10 and
11, particles were observed at 10 μM, but for 10 these
appeared to be precipitant rather than colloids and this
compound did not inhibit cruzain up to 10 μM. For com-
pound 11 particles were observed at 10 μM, as was enzyme
inhibition, but this inhibition was not reversible by deter-
gent, inconsistent with colloidal aggregation. Further-
more, no inhibition of AmpC β-lactamase was observed up
to 10 μMfor 9 and 11. Taken together with the well-behaved
dose-response curves (Figure 2), these results indicate
that the molecules are well behaved, classical binding
ligands.
All seven docking hits are specific for the A2A AR versus
the related A1 and A3 subtypes (Table 1). Notably, our most
potent ligand, compound 11, is also the most specific with
over 50-fold higher affinity at the A2A AR. We therefore
investigated five of its analogues not picked in the first round
of docking that also fit well into the site (compounds 14-18,
Table 2). Four of the analogues were found to bind to the
A2A AR with submicromolar affinities, and these molecules
also had an improved A2A/A1 subtype selectivity. From
these results, the prospects of identifying specific high-affi-
nity A2A antagonists in this new class of compounds appear
promising.
To put the results from this docking screen in perspective,
our laboratory considers a high-throughput docking screen
to be successful if a hit rate of 5%with ligand affinities in the
micromolar range can be achieved. For example, we tested
56 compounds from a docking screen against AmpC
β-lactamase and found one compound with aKi value better
than 100 μM, corresponding to a hit rate of 2%;29 this
inhibitor had a Ki value of 26 μM (Table 3). In the case
of the A2A AR we observe 10-fold higher hit rate and the
affinities of the hits are 10- to 100-fold better. Intriguingly,
similar results were obtained in two docking screens against
the other pharmaceutically relevant GPCR for which a
crystallographic structure has been solved, the β2 adrenergic
receptor.19,20 Kolb et al. identified six previously unknown
ligands of the β2 adrenergic receptor, a 24% hit rate, with
affinities as high as 9 nM.19 It may be that GPCRs are
particularly well-suited for structure-based docking screens,
a point to which we will return.
Predicted Binding Modes, Novelty, and Efficacy of the
Discovered A2A AR Ligands. All seven of the new ligands
are predicted to interact with the key recognition residue
Asn253 in transmembrane helix 6 and many also hydrogen-
bond with the carboxylate of Glu169 in extracellular loop 2,
both in the orthosteric site of the receptor (Figure 1). The
importance of interactions with Asn253 was identified early
in our docking screens. We found that increasing the dipole
moment of the Asn253 side chain amide, a technique we
employ frequently, substantially increased the enrichment of
known A2A AR ligands among a database of decoys in
Figure 2. Representative dose-response curves for displacement
of binding of the radiolabeled A2A AR agonist 3 by compounds 9,
10, and 11.
Table 2. Binding Affinities and Structures of Five Analogues to Compound 11 in Radioligand Binding Assays at A1, A2A, and A3 ARs
aMeasured in three independent experiments.
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control calculations. Asn253 is conserved in all four AR
receptor subtypes and has also been found to be a crucial
interaction partner for both agonists and antagonists in
mutagenesis studies.52
Whereas all the seven ligands are previously uncharacter-
ized for the A2A AR, some of them bear known chemotypes.
To quantify their novelty, or lack of it, we calculated the
similarity of each molecule to 7500 known AR ligands from
the WOMBAT and ChEMBL databases using pairwise
Tanimoto coefficients (Tc, ECFP4 fingerprints) (Table 1).
Ligand 12 resembles members of the xanthine class of
antagonists, while compound 7 resembles certain quinazo-
line53 ligands. Conversely, whereas compounds 10, 11, and
13 do conserve several moieties with known ligands, they
also differ substantially from them, with Tc values of 0.3 to
the closest annotated ligand. Nevertheless, they complement
the site well both sterically and electrostatically (Figure 1).
The potency of these molecules suggests that they may
merit further study as new lead families for antagonists of
the A2A AR.
To determine the efficacy of the compounds, their ability
to inhibit intracellular cAMP production induced by
agonist 3 was tested. No stimulation of cAMP production
was detected for any of the molecules, while a clear displace-
ment of agonist function was observed for the two most
potent compounds, 9 and 11 (Figure 3). All seven of the new
ligands are thus almost certainly A2A antagonists, as is the
cocrystallized ligand. Intriguingly, this efficacy bias was also
observed in the docking screens against the β2 adrenergic
receptor, where only inverse agonists were found against the
structure crystallized with the inverse agonist carazolol. In
docking to rigid GPCR structures, the protein conformation
may bias the screen toward molecules with the same efficacy
as the cocrystallized ligand. This represents a challenge to
our ability to exploit these structures for mechanisms of
action, such as agonism, not represented in the experimental
structure. To further investigate this, we determined the rank
of two agonists, 1 and 2 (Chart 1), that were present in the set
of commercially available molecules screened against the
A2A AR binding site. Whereas multiple known antagonists
would have been ranked among the top 500 molecules in the
docking screen, these two agonists were ranked 951 057 and
919 993, respectively.
Is There Library Bias toward GPCR Chemotypes in Che-
mical Libraries? Returning to one of the questions that
motivated this study, the structure-based screen against the
A2A AR returned a diverse set of ligands dissimilar to those
previously characterized, as well as several similar to known
ligands, and did so with a hit rate of 35%. Not only is this hit
rate much higher than we have come to expect for enzyme
targets screened with the same approach, but the new antago-
nists were also close to 100-fold more potent than we have
come to expect for our docking “hits”. Furthermore, these
results are strikingly similar to those observed in docking
screens against the β2 adrenergic GPCR.
19,20 To what may
these unusually high hit rates and affinities be attributed?
Family A GPCRs like the A2A AR are the targets for a
substantial fraction of marketed drugs, and this partly
reflects the quality of their sites for specific recognition of
smallmolecules. Largely buried frombulk solvent, these sites
can almost completely enclose a “druglike”molecule and can
do so with a mixture of nonpolar and polar interactions.
Consequently, a large and sustained medicinal chemistry
effort has focused on these targets, and by now even puta-
tively unbiased libraries, like ZINC, have become populated
with molecules bearing “GPCR-like” chemotypes. This also
reflects a bias toward naturally occurring molecules in our
screening libraries.54 Indeed, Kolb et al. estimated that there
were 3-12 times as many small molecules that were similar
toGPCR ligands in the ZINC leadlike set compared to other
common drug targets such as kinases, proteases, and ligand-
gated ion channels.19 Tomake this comparisonmore specific
and relevant to the adenosine receptor versus other docking
targets that we ourselves have worked, we investigated the
library bias in ZINC for the adrenergic and adenosine
receptors together with two other targets for which we have
observed much lower hit rates and affinities19,29,55 (Table 3).
The number of molecules in the ZINC leadlike set that are
similar to the ligands of these targets was estimated using
SEA,54 insisting on a P value of 10-10 or better; acceptable
molecules had also to resemble the annotated ligands in their
physical properties (see Methods). Over 4000 small mole-
cules resemble ligands annotated to the ARs and adrenergic
receptors in theWOMBAT39 database, almost 10-fold more
than found for the enzymes adenylyl cyclase and AmpC
β-lactamase, against which, correspondingly, our docking
hit rates and affinities have been 10- to 100-fold lower. Thus,
it is the convolution of the high “ligand-ability” of the
orthosteric sites and the many GPCR-like chemotypes in
Table 3. Target Library Bias and Docking Hit Rates
representative DOCK screen
target no. of ZINC molecules similar to known ligandsa hit rateb (%) best potencyc (nM)
adenosine receptors 4240 35 200
adrenergic receptors 4146 24 919
adenylyl cyclases 565 4 5000055
AmpC β-lactamase 545 2-5 2600029
aZINC leadlike molecules with at least 10-10 P values to annotated target ligands in WOMBAT using the similarity ensemble approach (SEA).
b (Number of true ligands)/(number of predictions tested experimentally). cThe affinity of the ligand with the best potency from the docking screen.
Figure 3. Functional assay based on measuring the production of
cAMP for 3 (control), a potent A2A AR agonist, with or without
10 μM 9 or 11. The dose-response curve is shifted for both
compounds, as expected in the case of competitive antagonistic
inhibition. The% activation refers to production of cAMP normal-
ized to the effect of 3 at 100 μM.
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our libraries that makes the adrenergic and adenosine re-
ceptors so fruitful for structure-based techniques.
Note Added after Initial Review of This Paper. After this
paper was submitted for review, a paper by Abagyan,
Stevens, and colleagues appeared that also targeted the
A2AAR for novel inhibitor discovery, also using amolecular
docking screen.56 As here, Abagyan et al. also observed a
very substantial hit rate with high affinities (indeed, both the
affinities and hit rates were slightly better than those we
observe). Whereas the compounds discovered in the two
screens were substantially different, the observation of the
high hit rates and, by screening standards, high affinity
“hits” is consistent with the high “ligand-ability” of the class
A GPCRs and the fortuitous library bias toward them, and
this is among the important conclusions of this study.
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